

NCIC CLINICAL TRIALS GROUP

GENITO URINARY

AGENDA

DISEASE SITE COMMITTEE MEETING

Delta Chelsea Hotel, Toronto, ON

Saturday, May 3, 2008

9:00 a.m. – 3:30 p.m.

Room: Rossetti

Chair: Fred Saad

-
- 9:00 WELCOME, APPROVAL OF FALL MEETING MINUTES**
Chairman's Report: NCI US Grant, Executive Retreat Fred Saad
- 9:10 NCIC CTG PHASE III TRIALS: OPEN**
BL 8 / EORTC 30994 L. Wood / A. Aprikian
BL.11 L. Lacombe
PR.8/SWOG 9346 B. Donnelly
PR.11 L. Klotz
PR.12 M. McKenzie / K. Chi
PR.13 (RADICALS) / MRC PR.10 C. Catton / F.Saad
PRP.1B – open to accrued patients N. Fleshner
- 10:10 NCIC CTG PHASE III TRIALS: CLOSED**
PR.7/PR.7 Bone Sub Study J. Crook / L.Klotz
PR.3 P. Warde
PRP.1 N. Fleshner
- NCIC CTG TRIALS APPROVED/PENDING ACTIVATION**
None
- 10:30 BREAK**
- 10:50 CTSU TRIALS ENDORSED/ACTIVATED BY NCIC CTG**
PRC.2/CALGB 90202 HT with or without zoledronic acid
in hormone naïve met CaP F. Saad
PRC.3/CALGB 90203 Neoadjuvant Taxotere plus AS
prior to RP v.s. RP only M.Gleave
REC.2/ECOG 2805 Sunitinib/placebo or Sorafenib / Placebo
in resected RCC M. Jewett / L.Wood
- CTSU TRIALS PENDING ENDORSEMENT/ACTIVATION**
None

continued...

- 11:20 NCIC CTG IND TRIALS**
 IND.165 Randomized Phase II (OGX-011 +/- docetaxel HRPC) (closed) K. Chi
- 11:25 OPEN CUOG TRIALS**
- | | | |
|------------|---|-------------------------------|
| CUOG-R-05 | Role of Delayed Treatment for Early Stage RCCa | M. Jewett |
| CUOG-P-05 | RCT Risedronate vs Placebo for the Prevention of Androgen Deprivation Bone Loss in Non-Metastatic Prostate Cancer | F. Saad |
| CUOG/CURC | CHICS Trial | L. Klotz |
| CUOG P-06a | Phase III trial of docetaxel +/- high dose Calcitriol | K. Chi |
| CUOG P-06b | Phase II Study of Patupilone (Epo906a) As A 2nd Line Therapy in HRPC | K. Chi |
| CUOG P-06c | Phase II Study of OGX-011 + mitoxantrone vs. OGX-011 + docetaxel as A 2nd Line Chemotherapy in HRPC | F. Saad / E. Winquist |
| | Sutent as salvage therapy in NSGCT | C. Kollmannsberger |
| | IAS plus dutasteride in PSA failures | L. Klotz / S.Larry Goldenberg |
| | ELAAT – early vs Late Androgen Ablation Therapy | A. Loblaw |
- PENDING CUOG TRIALS**
 None
- 12:15 LUNCH**
- 1:20 CLOSED CUOG TRIALS**
- | | |
|--|-------------|
| Taxotere as Second Line in HRPC | F. Saad |
| Iressa for Rising PSA post RP | L. Klotz |
| CUOG B-05 BMS/CUOG second line bladder trial with vinflunine | E. Winquist |
- 1:40 TRIALS UNDER DEVELOPMENT: CUOG**
- | | |
|---|-------------------|
| Phase II Study of SU011248 for maintenace therapy in HRPC after 1st line Chemotherapy | B.Eigl |
| Second-line bladder study (single arm Abraxane) | Y.Ko |
| Randomized, placebo-controlled Phase II Study of SU011248 plus Best Supportive Care (BSC) versus Placebo <u>plus BSC</u> in patients with advanced urothelial carcinoma who have failed cisplatin containing chemotherapy | T. Cheng |
| Temsirolimus second line RCC trial in Sutent Failure | F. Saad / L. Wood |
- 2:30 NEW TRIAL PROPOSALS**
 None for NCIC CTG
 VEG TRAP (R1R2) proposal for CUOG
- 3:00 OPEN DISCUSSION - NEW BUSINESS, STRATEGIC PLANNING**
 Identifying liaisons between other working groups within the NCIC CTG (i.e. correlative sciences/tumour banking working group, psychosocial research working group, RTQA, etc)
- 3:30 GU Executive (Closed)**